LGNDLigand Pharmaceuticals Incorporated

Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while traditional market multiples suggest the shares are pricing in a richer outlook. Ligand Pharmaceuticals has delivered a very large 5 year return of 337.4%, which puts extra focus on whether the current price still offers a margin of safety. The recent expansion of its royalty portfolio and...

Ligand Pharmaceuticals (LGND) is back in focus after its recent second quarter report and reaffirmed 2026 guidance. The company posted US$63.69 million in quarterly revenue and US$48.51 million in net income. See our latest analysis for Ligand Pharmaceuticals. The latest earnings report and reaffirmed 2026 guidance have come after a strong run for Ligand Pharmaceuticals, with a 90 day share price return of 33.93% and a 1 year total shareholder return of 87.99%. If this kind of multi year...

XOMA acquisition and convertible financing boost 2026 guidance to $9.00–$9.50 per share.

On the IBD 50 and the latest list of new buys by top funds, Ligand stock targets a breakout but faces this test first.

Adjusted EPS jumps 48% to $2.37, driven by Filspari and Otuber strength, while the transformative Zoma deal adds over 120 assets and $2.3 billion in milestone potential.

Moby summary of Ligand Pharmaceuticals Incorporated's Q2 2026 earnings call

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

Ligand stock landed in a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big Pharma royalties.

Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls

Wall Street analysts are making bold moves on Tuesday, shaking up ratings for some of the biggest names in tech, biotech, and retail in ways that could catch investors off guard. Find out which stocks got slashed and which ones earned surprise upgrades.

Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while market multiples and a low overall value score point to a richer pricing. The 338.7% three year return puts a spotlight on whether the current price already embeds much of the good news in Ligand Pharmaceuticals. The completed US$739m...

Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.

Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company announced an oversubscribed private placement of up to $340 million to support development of its botensilimab and balstilimab (BOT+BAL) immunotherapy combination in microsatellite-stable (MSS)...

Oxford Club strategist Marc Lichtenfeld highlights diversification beyond tech, spotlighting Ligand Pharmaceuticals, Aflac and Atlantic Union Bankshares as healthcare, insurance and banking stocks gaining quiet momentum.

Private Placement Strengthens Funding PositionAgenus Inc. (NASDAQ:AGEN) shares climbed 13% in premarket trading on Monday after the biotechnology company announced an $85 million private placement designed to strengthen its balance sheet and support the continued development of its clinical pipeline.